Biased Ligands. Better Drugs.

Biased Ligand Products

Cardiovascular Program

Although Trevena's biased GPCR ligand technology is potentially applicable across a wide range of drug targets and diseases, our pipeline of wholly owned differentiated biased ligand drugs is currently focused on CNS diseases.

Recent Product News

Related Events

  • IASP World Congress on Pain, Buenos Aires, Argentina10/06/2014 - 10/11/2014

    Rosamond Deegan - Senior Vice President, Business Development and Franck Skobieranda, VP Clinical Development, will be attending the International Association for the Study of Pain 15th World Congress on Pain, October 6th - October 11th 2014 in Buenos Aires, Argentina.

    Details on the conference, can be found at the IASP website.

  • 13th Annual ASRA Pain Medicine Meeting, San Francisco, California11/13/2014 - 11/16/2014

    Dr. Michael Lark, CSO, will be attending the American Society of Regional Anesthesia and Pain 13th Annual Pain Medicine Meeting in San Francisco, California from 13th to 16th of November 2014.

    Details on the meeting, can be found at the ASRA website.

Copyright © Trevena, Inc.